Advertisements


Goldman says Bristol-Myers reaction to NSCLC data, Merck news "way overdone"

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018

Bristol reaction to NSCLC data, Merck news "way overdone," says Goldman Sachs

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018

Bristol-Myers announces CNDA approval of Opdivo for NSCLC treatment

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 15th, 2018

Nektar, Bristol-Myers announce preliminary data from PIVOT Phase 1/2 study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 3rd, 2018

Bristol-Myers reports patient-reported outcomes data from CheckMate-214 trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 1st, 2018

Bristol-Myers downgraded on lung cancer data disappointment at Morgan Stanley

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 17th, 2018

Biotech Analysis Central Pharma News: Merck"s Keytruda Breakthrough, Bristol Myers And JNJ Team Up, Alkermes Gets A Second Shot

Biotech Analysis Central Pharma News: Merck"s Keytruda Breakthrough, Bristol Myers And JNJ Team Up, Alkermes Gets A Second Shot.....»»

Category: topSource: seekingalphaApr 17th, 2018

Merck Cements Lead in Lung Cancer as Bristol-Myers Fizzles

Merck & Co. might have just shut the door on rival Bristol-Myers Squibb Co. as investors weigh new data that could reshape the treatment of lung cancer, by far the deadliest form of cancer in the U.S......»»

Category: topSource: moneycentralApr 16th, 2018

Nektar shares drop 16% to $84.50 after Bristol-Myers cancer data

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018

Bristol-Myers Reports Positive Data in NSCLC Trial on Opdivo

Bristol-Myers Squibb Company (BMY) announced positive results from the phase III trial, CheckMate -0.....»»

Category: worldSource: nytApr 16th, 2018

Merck rises, Bristol-Myers slides following cancer meeting

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018

Bristol-Myers announces EMA validated type II application for Empliciti

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 18th, 2018

Friday’s Vital Data: Apple, Advanced Micro Devices and Merck

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Goldma.....»»

Category: topSource: investorplaceSep 14th, 2018

Natera in pact with Bristol-Myers in lung cancer study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 13th, 2018

Bristol-Myers files automatic mixed securities shelf

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 12th, 2018

Bristol-Myers" TYK2 efficacy looks better than Otezla, says Credit Suisse

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 12th, 2018

Bristol-Myers says efficacy endpoints achieved in Phase 2 study of BMS-986165

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 12th, 2018

Bristol-Myers" TYK2 inhibitor may be underappreciated asset, says Morgan Stanley

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 6th, 2018

H.C. Wainwright impressed by first ever TIL data in NSCLC

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 6th, 2018

Why Bristol-Myers Squibb Is a Great Dividend Stock

InvestorPlace - Stock Market News, Stock Advice & Trading Tips .....»»

Category: topSource: investorplaceSep 5th, 2018

First Data price target raised to $30 from $28 at Goldman Sachs

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 30th, 2018